Cefroxadine

The antibacterial spectrum of cefroxadine was as wide as that of CEX, and its antibacterial effect was as strong as that of CEX or even 2-fold stronger against E. coli and Klebsiella. Cefroxadine was also proved to have stronger bactericidal or bacteriolytic effect than CEX and have better affinity...

Full description

Saved in:
Bibliographic Details
Published inJapanese journal of antibiotics Vol. 35; no. 6; p. 1365
Main Author Mashimo, K
Format Journal Article
LanguageJapanese
Published Japan 01.06.1982
Subjects
Online AccessGet full text
ISSN0368-2781

Cover

Abstract The antibacterial spectrum of cefroxadine was as wide as that of CEX, and its antibacterial effect was as strong as that of CEX or even 2-fold stronger against E. coli and Klebsiella. Cefroxadine was also proved to have stronger bactericidal or bacteriolytic effect than CEX and have better affinity with penicillin binding proteins. In clinical trials, an efficacy rate of 82.7% was achieved in a total of 2,009 cases of various infections analyzed. Cefroxadine displayed particularly good clinical and bacteriological effects for the infections of skin, soft tissues, respiratory tract and urinary tract. The rate of bacteria eradication in a total of 1,410 cases was 81.6%, showing good results against the bacteria such as S. aureus (83.9%, 167/199), E. coli (89.0%, 528/593), Klebsiella (78.0%, 78/100) and P. mirabilis (80.0%, 36/45). As for side effects, their incidence was a low of only 2.3%, the main ones being eruption and gastrointestinal symptoms just as recognized in conventional cephalosporins, and none of them was serious. Abnormal laboratory test values were only increases in eosinophil, S-GOT, S-GPT and Al-P values, and their incidence was low. From these findings, we may say that the drug is an effective, safe, and useful antibiotic among all other orally administered cephalosporins.
AbstractList The antibacterial spectrum of cefroxadine was as wide as that of CEX, and its antibacterial effect was as strong as that of CEX or even 2-fold stronger against E. coli and Klebsiella. Cefroxadine was also proved to have stronger bactericidal or bacteriolytic effect than CEX and have better affinity with penicillin binding proteins. In clinical trials, an efficacy rate of 82.7% was achieved in a total of 2,009 cases of various infections analyzed. Cefroxadine displayed particularly good clinical and bacteriological effects for the infections of skin, soft tissues, respiratory tract and urinary tract. The rate of bacteria eradication in a total of 1,410 cases was 81.6%, showing good results against the bacteria such as S. aureus (83.9%, 167/199), E. coli (89.0%, 528/593), Klebsiella (78.0%, 78/100) and P. mirabilis (80.0%, 36/45). As for side effects, their incidence was a low of only 2.3%, the main ones being eruption and gastrointestinal symptoms just as recognized in conventional cephalosporins, and none of them was serious. Abnormal laboratory test values were only increases in eosinophil, S-GOT, S-GPT and Al-P values, and their incidence was low. From these findings, we may say that the drug is an effective, safe, and useful antibiotic among all other orally administered cephalosporins.The antibacterial spectrum of cefroxadine was as wide as that of CEX, and its antibacterial effect was as strong as that of CEX or even 2-fold stronger against E. coli and Klebsiella. Cefroxadine was also proved to have stronger bactericidal or bacteriolytic effect than CEX and have better affinity with penicillin binding proteins. In clinical trials, an efficacy rate of 82.7% was achieved in a total of 2,009 cases of various infections analyzed. Cefroxadine displayed particularly good clinical and bacteriological effects for the infections of skin, soft tissues, respiratory tract and urinary tract. The rate of bacteria eradication in a total of 1,410 cases was 81.6%, showing good results against the bacteria such as S. aureus (83.9%, 167/199), E. coli (89.0%, 528/593), Klebsiella (78.0%, 78/100) and P. mirabilis (80.0%, 36/45). As for side effects, their incidence was a low of only 2.3%, the main ones being eruption and gastrointestinal symptoms just as recognized in conventional cephalosporins, and none of them was serious. Abnormal laboratory test values were only increases in eosinophil, S-GOT, S-GPT and Al-P values, and their incidence was low. From these findings, we may say that the drug is an effective, safe, and useful antibiotic among all other orally administered cephalosporins.
The antibacterial spectrum of cefroxadine was as wide as that of CEX, and its antibacterial effect was as strong as that of CEX or even 2-fold stronger against E. coli and Klebsiella. Cefroxadine was also proved to have stronger bactericidal or bacteriolytic effect than CEX and have better affinity with penicillin binding proteins. In clinical trials, an efficacy rate of 82.7% was achieved in a total of 2,009 cases of various infections analyzed. Cefroxadine displayed particularly good clinical and bacteriological effects for the infections of skin, soft tissues, respiratory tract and urinary tract. The rate of bacteria eradication in a total of 1,410 cases was 81.6%, showing good results against the bacteria such as S. aureus (83.9%, 167/199), E. coli (89.0%, 528/593), Klebsiella (78.0%, 78/100) and P. mirabilis (80.0%, 36/45). As for side effects, their incidence was a low of only 2.3%, the main ones being eruption and gastrointestinal symptoms just as recognized in conventional cephalosporins, and none of them was serious. Abnormal laboratory test values were only increases in eosinophil, S-GOT, S-GPT and Al-P values, and their incidence was low. From these findings, we may say that the drug is an effective, safe, and useful antibiotic among all other orally administered cephalosporins.
Author Mashimo, K
Author_xml – sequence: 1
  givenname: K
  surname: Mashimo
  fullname: Mashimo, K
BackLink https://www.ncbi.nlm.nih.gov/pubmed/6752462$$D View this record in MEDLINE/PubMed
BookMark eNotjrtqxDAQRVVs2Gyc_YS06Qx6zUgqg8kLFtJsb0byCBz82FgxJH-fhbg6zTmXeyd20zzxThykQV9r59WtOJbSRym11yoE2Is9OtAW9UFUDedl_qGun_he3GQaCh83VuL88nxu3urTx-t783SqP5XUusaOzLVHUt4Hw1qnHMAlC8hkbHIMwCEwUOgYM6jobUaKCsjbFJ2pxOP_7GWZv1Yu3-3Yl8TDQBPPa2mdVShDsFfxYRPXOHLXXpZ-pOW33c6bP_edP4Q
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID 6752462
Genre Clinical Trial
Journal Article
Review
GroupedDBID .55
3O-
53G
5GY
7.U
8GM
ALMA_UNASSIGNED_HOLDINGS
CGR
CUY
CVF
ECM
EIF
F5P
JSF
JSH
KQ8
NPM
OK1
RJT
RZJ
SJN
TKC
X7J
X7M
ZJWQK
ZXP
7X8
ID FETCH-LOGICAL-j1022-6da36756a18893e22cf957c456ea34c7e55e99e5a9de6f51b84f6ab15a84cb73
ISSN 0368-2781
IngestDate Fri Jul 11 09:53:53 EDT 2025
Tue Aug 05 11:35:05 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Language Japanese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j1022-6da36756a18893e22cf957c456ea34c7e55e99e5a9de6f51b84f6ab15a84cb73
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
PMID 6752462
PQID 74160994
PQPubID 23479
ParticipantIDs proquest_miscellaneous_74160994
pubmed_primary_6752462
PublicationCentury 1900
PublicationDate 1982-Jun
19820601
PublicationDateYYYYMMDD 1982-06-01
PublicationDate_xml – month: 06
  year: 1982
  text: 1982-Jun
PublicationDecade 1980
PublicationPlace Japan
PublicationPlace_xml – name: Japan
PublicationTitle Japanese journal of antibiotics
PublicationTitleAlternate Jpn J Antibiot
PublicationYear 1982
SSID ssib002821995
ssib058493060
ssj0000884033
Score 1.3053411
SecondaryResourceType review_article
Snippet The antibacterial spectrum of cefroxadine was as wide as that of CEX, and its antibacterial effect was as strong as that of CEX or even 2-fold stronger against...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 1365
SubjectTerms Adolescent
Adult
Aged
Animals
Bacteria - drug effects
Bacterial Infections - drug therapy
Bacterial Infections - microbiology
Cephalosporins - therapeutic use
Cephradine - adverse effects
Cephradine - analogs & derivatives
Cephradine - metabolism
Cephradine - pharmacology
Cephradine - therapeutic use
Child
Child, Preschool
Clinical Trials as Topic
Drug Resistance, Microbial
Female
Humans
Male
Mice
Middle Aged
Pregnancy
Rabbits
Rats
Title Cefroxadine
URI https://www.ncbi.nlm.nih.gov/pubmed/6752462
https://www.proquest.com/docview/74160994
Volume 35
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  issn: 0368-2781
  databaseCode: KQ8
  dateStart: 19680101
  customDbUrl:
  isFulltext: true
  dateEnd: 20081231
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  omitProxy: true
  ssIdentifier: ssj0000884033
  providerName: Colorado Alliance of Research Libraries
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba8IwFA7Tp-1h7CZz1z4Mn-ywadKmj0MUGeocVPCtJG0KCrNOK8z9-p30PtjY5SW0gYbmfO3Jd5JzQeiOwapHmOA64T7VSQiNwD7WJRWMisCkEqvY4dHYGkzJ44zOyoJMSXRJLO799y_jSv6DKvQBripK9g_IFoNCB1wDvtACwtD-CuOuDNfRm_KC_-zQAwugKixZTQsBApyLeRRXnNtHqo7SS1TudQZpNByQ4cJJqQh6ApHYadWTXKGl-T8y4KraSbm0lXo_P-seP3n96XDoub2Z21q96qoilzq5zsqT1FANdII67n6uGCYMq9ju_B5YjAO2R6fY3QLdRTpmWps6e8PvKXyylLtH6DDj4NpDKtBjtLfgJ6g1SZN479qaW8akbdpaS5uU6b13p-igIvUz5PZ7bnegZyUl9IUybXUr4CaYSBY3GBA1ibEfOtT2gUVKbhLflpRKx5GUO4G0QmoIRkKLC4NyRnxhmw1UX0ZLeY40k_kiSWdoWQ5MlQDxCZgIBTYDI8TCbqLbfLoe_LHqGAagj7YbT3Fg4OWkiRqpFLxVmljEgzeD8fDFj49eov3ya7hC9Xi9lddAjmJxk-D0Abw9EM0
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cefroxadine&rft.jtitle=Japanese+journal+of+antibiotics&rft.au=Mashimo%2C+K&rft.date=1982-06-01&rft.issn=0368-2781&rft.volume=35&rft.issue=6&rft.spage=1365&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0368-2781&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0368-2781&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0368-2781&client=summon